Northwire Canada EditionFriday, July 17, 2026
Sign inSubscribe
Northwire
⌕
LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8% LUN 33.59 −2.5% NTR 94.27 −1.8% LALI 0.055 −8.3% SCD 0.170 +0.0% HWY 0.370 +0.0% FCI 0.385 +1.3% GGAU 0.180 −5.3% KIRO 0.650 +1.6% LBNK 0.430 +0.0% BARU 0.040 +0.0% VCU 1.09 −4.4% NOBL 0.095 −5.0% SHL 0.355 +0.0% MTS 0.130 +0.0% FYL 0.090 +0.0% NUAG 5.55 +1.8%

Healthcare

Page 97
  1. Nov 21, 2025 · 18:01 · FNDX

    FendX Provides Corporate Update

    FendX Provides Corporate Update

    01
  2. Nov 21, 2025 · 17:53 · CNVI

    Conavi files prospectus for share offering

    Conavi files prospectus for share offering

    02
  3. Nov 21, 2025 · 16:56 · RVV

    Revive talks DRDC study on bucillamine for nerve agents

    Revive talks DRDC study on bucillamine for nerve agents

    03
  4. Nov 21, 2025 · 16:30 · CNVI

    Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

    Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

    04
  5. Nov 21, 2025 · 12:07 · RVV

    Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

    Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study

    05
  6. Nov 20, 2025 · 23:50 · ONCO

    Onco-Innovations partner begins A83B4C63 scale-up

    Onco-Innovations partner begins A83B4C63 scale-up

    06
  7. Nov 20, 2025 · 19:55 · NXG

    NexgenRx Announces Significant Third Quarter Revenue and EBITDA Growth

    NexgenRx Announces Significant Third Quarter Revenue and EBITDA Growth

    07
  8. Nov 20, 2025 · 19:30 · ONCO

    Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies

    Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies

    08
  9. Nov 20, 2025 · 18:02 · HEM

    Hemostemix's ACP-01 dementia trial to be led by Shankle

    Hemostemix's ACP-01 dementia trial to be led by Shankle

    09
  10. Nov 20, 2025 · 17:34 · BCT

    Briacell, Receptor.AI to work on kinase inhibitors

    Briacell, Receptor.AI to work on kinase inhibitors

    10
  11. Nov 20, 2025 · 17:30 · RX

    BioSyent Releases Financial Results for Q3 and YTD 2025

    BioSyent Releases Financial Results for Q3 and YTD 2025

    11
  12. Nov 20, 2025 · 17:29 · IOT

    Innovotech closes $200K convertible debenture financing

    Innovotech closes $200K convertible debenture financing

    12
  13. Nov 20, 2025 · 17:00 · WOLF

    GREY WOLF ANIMAL HEALTH REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    GREY WOLF ANIMAL HEALTH REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS

    13
  14. Nov 20, 2025 · 15:41 · WELL

    Well Health talks clinic digitization, patient openings

    Well Health talks clinic digitization, patient openings

    14
← Newer Older →